An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

Bennie, M. and Black, C. and Cairns, V. and Hems, S. and Mciver, L. and Nicholson, J. and Oduro, S. and Payne, R. and Ramsay, W. (2009) An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders. Basic and Clinical Pharmacology and Toxicology, 105 (Supp.1). p. 92. ISSN 1742-7835 (https://doi.org/10.1111/j.1742-7843.2009.00437.x)

Full text not available in this repository.Request a copy

Abstract

A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug and Therapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

ORCID iDs

Bennie, M. ORCID logoORCID: https://orcid.org/0000-0002-4046-629X, Black, C., Cairns, V., Hems, S., Mciver, L., Nicholson, J., Oduro, S., Payne, R. and Ramsay, W.;
CORE (COnnecting REpositories)